ABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis

(marketscreener.com) Based on encouraging Phase 2a data and a productive pre-IND Type B meeting with U.S. Food and Drug Administration , ABIONYX Pharma intends to file an Investigational New Drug application in the coming months which will include